Wegovy Now Prescribed by GPs to Prevent Heart Attacks and Strokes: What You Need to Know

Why Are GPs Now Prescribing Wegovy for Heart Disease Prevention?

The decision to allow general practitioners to prescribe Wegovy for cardiovascular prevention marks a major shift in how weight-related heart disease risk is managed. Until now, access to semaglutide 2.4 mg for this indication was largely restricted to specialist obesity or cardiology services. The move follows growing recognition that cardiovascular disease remains the leading cause of death globally, and that obesity is one of its most significant modifiable risk factors.

The pivotal evidence comes from the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in The New England Journal of Medicine in 2023. This randomized, double-blind trial enrolled more than 17,600 adults aged 45 and older who had established cardiovascular disease and a BMI of 27 or greater, but who did not have diabetes. Over a mean follow-up of approximately 40 months, participants receiving semaglutide 2.4 mg weekly experienced a 20% reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke compared with placebo.

Who Is Eligible for Wegovy as a Cardiovascular Preventive Treatment?

The expanded prescribing authorization targets a specific patient population: adults with pre-existing cardiovascular disease — such as a prior heart attack, stroke, or peripheral artery disease — who also have overweight or obesity. This mirrors the inclusion criteria of the SELECT trial. Importantly, the cardiovascular benefit was observed independently of the degree of weight loss, suggesting that semaglutide's protective effects may involve direct actions on blood vessels, inflammation, and metabolic pathways beyond simple weight reduction.

GPs are expected to assess patients individually, considering factors such as existing medications, kidney function, and gastrointestinal tolerance, since nausea and gastrointestinal side effects are the most commonly reported adverse reactions with GLP-1 receptor agonists. The treatment involves a gradual dose escalation over several months to reach the maintenance dose of 2.4 mg per week. Health authorities have emphasized that Wegovy in this context is not a cosmetic weight loss prescription but a targeted cardiovascular risk reduction strategy, and prescribing guidelines reflect this clinical distinction.

What Are the Broader Implications for Cardiovascular Prevention?

The approval of a GLP-1 receptor agonist for cardiovascular prevention in primary care represents a fundamental change in how clinicians approach heart disease risk. Traditionally, cardiovascular prevention has relied on statins, antihypertensives, and antiplatelet agents. Semaglutide now joins this arsenal as the first obesity medication with proven cardiovascular outcome benefits, validated in a large-scale randomized trial. The American Heart Association and the European Society of Cardiology have both acknowledged the significance of the SELECT trial data in recent guideline discussions.

However, questions remain about long-term cost-effectiveness, supply constraints, and ensuring equitable access. Semaglutide is among the most expensive preventive medications currently available, and demand already outstrips supply for its diabetes and weight management indications. Health economists and public health experts have called for careful implementation strategies to ensure that the patients who stand to benefit most — those at highest cardiovascular risk — are prioritized. As real-world prescribing data accumulate, the true population-level impact of this policy change will become clearer.